This action was surfaced by Law.com Radar, which delivers real-time alerting on new litigation across more than 2,600 state and federal courts. Click here to get started and be first to act on ...

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...

Pfizer has officially kissed goodbye to its consumer health venture by selling its final 7.3% stake in Haleon for a tidy $3.3 ...

NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada; Potential for revenue in Canada alone of $100-150 million dollars. PrimeC Has Previously ...

This year's gearing up to be a wild ride for stocks and shares so investors should consider a careful approach to their ISA ...

Show Full Article The main part of their brain that is damaged is ... Between 6 per cent and 17 per cent of people with RLS who take dopamine agonists develop some form of impulse-control disorder, ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...